explore -WSS

explore

author：knowledge 2025-09-30 15:22:29 - browse：18683

Duchenne muscular dystrophy Histopathology — Duchenne muscular dystrophy histopathology. Dr. Edwin P. Ewing, Jr./CDC

Japanese drugmaker Nippon Shinyaku said on Monday that its Duchenne muscular dystrophy drug, Viltepso, part of a controversial class of treatments for the rare disease, had failed to reach its primary endpoint in a placebo-controlled confirmatory trial.

Children who received the drug could stand up faster from the floor at the end of the study, but so could children who received a placebo. There was no statistically significant difference between the groups.

Although Nippon did not release detailed data, the failure is notable because Viltepso belongs to a contentious class of drugs called exon-skippers. Duchenne is caused by mutations in a muscle-supporting gene called dystrophin. These drugs are designed to increase the amount of dystrophin protein that patients with specific mutations produce. But the drugs only lead to slight increases in protein levels, and their clinical benefits have never been proven in a large, placebo-controlled study.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Digital health funding stays low as a new reality sets in

focus

leisure time

WSS

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

After half a century, Israel moves to evict squatter from his cave home on the beach

Inflation cooled significantly in June, bringing price hikes close to normal levels

Va. Republicans encourage early voting, a target of Trump's, ahead of fall elections

Va. Republicans encourage early voting, a target of Trump's, ahead of fall elections

Sickle cell gene therapy cures need to be accessible in Africa

focus

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Superbugs, antibiotic resistance get scrutiny in congress

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Readout LOUD podcast: possible new ALS drug, artificial wombs

23andMe had bad news about my health. I wish a person had delivered it

Intarcia’s device

Jerome Adams on the need for new antivirals for Covid

Biotech stock slump in 2023: awaiting the turnaround

Duchenne breakthrough therapy leaves behind pioneering families

CDC's new outbreak response network to include Northeastern

explore

How AI helped researchers track recovery from depression

Cuban government calls US nuclear submarine stop a 'provocative escalation'

Senators: Long

Changes to biosimilar regulatory framework must prioritize patients

Tommy Tuberville reverses his claim that white nationalists are unfairly labeled racist

EU fines Illumina $475 million over Grail acquisition

focus

leisure time

Wikipedia

hotspot